Prerna Srivastava, Author at PharmaSource

Biotech Profile

VERIGRAFT – First Industrially Scalable Personalised Tissue Therapy Platform Advances to Pivotal Phase II

Swedish biotech VERIGRAFT outlines how it solved regenerative medicine’s manufacturing paradox, creating the first tissue therapy platform designed for industrial-scale production while maintaining patient personalisation. Founded in Gothenburg in 2014, VERIGRAFT has achieved what many considered impossible in regenerative medicine: developing

12 September 2025

Biotech Profile

GeoVax – From HIV Vaccine Pioneer to Multi-Platform Developer Targeting 40 Million Immunocompromised Americans

Atlanta-based biotech GeoVax outlines how its multi-antigen MVA platform addresses critical gaps left by single-antigen vaccines, with three Phase 2 COVID-19 trials underway and a Phase 3 Mpox vaccine trial scheduled for H2 2026 Founded in 2001 from Emory University’s

5 September 2025

Category Guide

Vaccine Manufacturing: Complete Guide to Process, Challenges, and Regulatory Compliance

Vaccine manufacturing represents one of the most complex and regulated segments within pharmaceutical production, combining cutting-edge biotechnology with stringent quality assurance protocols. The global vaccine contract manufacturing market is projected to grow from USD 2.38 billion in 2024 to USD

5 September 2025

Category Guide

mRNA Vaccines and Therapeutics CDMO Market Report

Messenger RNA (mRNA) vaccines and therapeutics have emerged as a transformative force in the pharmaceutical landscape, with the remarkable success of mRNA-based COVID-19 vaccines propelling this technology into the global spotlight. The mRNA CDMO market plays a vital role in

6 August 2025

Biotech Profile

Ciloa – First to Overcome 30-Year Challenge of Stable, Functional Recombinant Adiponectin Production

French biotech Ciloa outlines how 14 years of exosome engineering trials led to breakthrough adiponectin biotherapeutic now advancing toward Phase I trials in 2027. CEO Robert Z. Mamoun describes the transition from retrovirus research to developing what the company claims

6 August 2025

Biotech Profile

One Biosciences – First clinical-grade single-cell transcriptomic platform for FFPE samples targets tumor heterogeneity gap

Paris biotech One Biosciences outlines how single-cell transcriptomics can transform precision oncology by capturing the cellular complexity that traditional bulk sequencing misses. Founded by Institut Curie pioneer Dr. Céline Vallot, the company has secured over €20 million to bring OneMap™

4 August 2025

Biotech Profile

Priothera – From Novartis Shelved Asset to Phase 3 in Five Years

Irish biotech Priothera is advancing mocravimod, a non-immunosuppressive S1P receptor modulator that the founding team rescued from Novartis’ pipeline, now targeting improved survival outcomes for AML patients undergoing stem cell transplantation. Co-founder Dr. Simone Seiter outlines how strategic protocol amendments

4 August 2025

Biotech Profile

Alligator Bioscience – Engineering CD40 Agonism from Academic Roots to Phase 3 Readiness

Swedish biotech Alligator Bioscience outlines how strategic antibody engineering and focused execution positioned mitazalimab for pivotal trials in metastatic pancreatic cancer, transforming from university research into a Phase 3-ready immunotherapy program. Founded in 2001 and headquartered in Lund, Sweden, Alligator

4 August 2025

Biotech Profile

Minoryx – Only Brain-Penetrating PPAR-Gamma Agonist Reaches European Filing for Fatal Childhood Disease

Addressing an Aggressive Pediatric Disease with No Treatment Options Spanish biotech Minoryx has carved out a critical position in orphan CNS diseases by developing leriglitazone for X-linked adrenoleukodystrophy (X-ALD), a genetic condition where patients in the most aggressive phenotype face

4 August 2025

Expert Insight

Three Smart CMC Strategies: Maximising Every Euro for Emerging Biotechs

Unlocking Value Through Strategic Alignment and Flexibility Emerging biotech and pharmaceutical companies consistently face the intricate challenge of balancing time, cost, and risk. As these organisations strive to develop novel therapies and bring them to market, meticulous resource management is

11 June 2025

Prerna Srivastava News and Resources

VERIGRAFT – First Industrially Scalable Personalised Tissue Therapy Platform Advances to Pivotal Phase II

GeoVax – From HIV Vaccine Pioneer to Multi-Platform Developer Targeting 40 Million Immunocompromised Americans

Vaccine Manufacturing: Complete Guide to Process, Challenges, and Regulatory Compliance

mRNA Vaccines and Therapeutics CDMO Market Report

Ciloa – First to Overcome 30-Year Challenge of Stable, Functional Recombinant Adiponectin Production

One Biosciences – First clinical-grade single-cell transcriptomic platform for FFPE samples targets tumor heterogeneity gap

Priothera – From Novartis Shelved Asset to Phase 3 in Five Years

Alligator Bioscience – Engineering CD40 Agonism from Academic Roots to Phase 3 Readiness

Minoryx – Only Brain-Penetrating PPAR-Gamma Agonist Reaches European Filing for Fatal Childhood Disease

Three Smart CMC Strategies: Maximising Every Euro for Emerging Biotechs

Welcome to PharmaSource

Follow us

Top Links

Get in touch